30 closest matches · ranked by relevance
Epilepsy
Primary: Summary of 28-day Seizure Frequency for Sum of Individual Seizures and Clusters for 52-week OLE Period (Mean Percent Change & Standard Deviation) — -31.23; NA; 122.10…
PCDH19-Related Epilepsy
Primary: Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change) — -23.97; -61.52 Median % Change in Number of Seizures
Phelan-McDermid Syndrome · Epilepsy
Primary: Number of Adverse Events — 19 events
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
CDKL5 Deficiency Disorder
Primary: Summary of 28-day Seizure Frequency for Major Motor Seizure Types — 49.17; 54.00; 55.50; 45.03 Seizures per day
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
CDD
Primary: Change From Baseline in Median Monthly Convulsive Seizure Frequency — 88.429 Number of monthly seizures
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Epilepsy
Primary: Percent Change From Baseline in 28-Day Convulsive Seizure Frequency During Ataluren Treatment Period — 723.17 percent change
Developmental and/or Epileptic Encephalopathies
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants
15q Duplication Syndrome · CDKL5 Deficiency Disease
Primary: Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period — 11.7; -23.6 percent change
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Percent Change From Baseline in Seizure Frequency Per 28 Days During the Maintenance Period — 3.11; -27.76 percent change — p=0.0007
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Phelan-McDermid Syndrome
Primary: Safety and Tolerability — 17; 17; 1; 3 Participants
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Seizures
Primary: Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol — 59.03; 110.5; 256.9; 28.71 nanograms/milliliter (ng/mL)
Tuberous Sclerosis Complex · Epilepsy
Primary: Safety - Adverse Events — 40 percentage of participants
Highly Drug-resistant Focal Epilepsy
Primary: 75 % Responder Rate During the 2-week Inpatient Period — 11.1; 30.8 percentage of participants — p==0.0679
Tuberous Sclerosis
Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change
Partial Onset Seizures
Primary: Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase — 1.69; 1.15; 1.58 seizures per 24 hours — p=0.4606
Epilepsy
Primary: Completed MEG — 1 participants
Epilepsy
Primary: Change in Partial Onset Seizure (POS) Frequency Per 28 Days From Baseline to the Maintenance Period — -1.55; -3.05 Seizures per 28 days — p==0.0003
Central Nervous System
Primary: Apparent Clearance (CL/F) of Perampanel [Core Study] — 0.732; 0.956; 1.73; 1.92 Liter per hour